Aclaris Eyes Breakout on Upcoming Clinical Results
AI Prediction of Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, shows potential for significant stock price movement due to its focused development on novel drug candidates for immuno-inflammatory diseases. The recent inclusion in the Russell 2000 and 3000 indexes, alongside promising clinical trial advancements for its key drug candidates, positions ACRS as a potentially attractive investment opportunity.
ACRS Report Information
Prediction Date2025-07-03
Close @ Prediction$1.44
Mkt Cap169m
IPO Date2015-10-07
AI-derived Information
Recent News for ACRS
- Sep 30 — Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 (GlobeNewswire)
- Sep 21 — Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight (Insider Monkey)
- Sep 18 — Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? (Zacks)
- Sep 9 — Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
- Aug 27 — Aclaris Therapeutics to Participate in Two September Healthcare Conferences (GlobeNewswire)
- Aug 17 — Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138 (Insider Monkey)
- Aug 7 — Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
- Aug 7 — Aclaris: Q2 Earnings Snapshot (Associated Press Finance)
- Aug 7 — Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
- Aug 4 — Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.